Are primed polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis patients?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 2, 2008, Pages

  Cohen Mazor, Meital ^a,b   Sela, Shifra ^a,b   Mazor, Rafi ^a,b   Ilan, Neta ^a   Vlodavsky, Israel ^a   Rops, Angelique L ^c   Van Der Vlag, Johan ^c   Cohen, Hector I ^b   Kristal, Batya ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b WESTERN GALILEE HOSPITAL   (Israel)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Heparan sulfate

Indexed keywords

CD11B ANTIGEN; HEPARAN SULFATE; HEPARANASE; PROTEOGLYCAN; SUPEROXIDE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MALE; NEUTROPHIL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; ATHEROSCLEROSIS; CELL DEGRANULATION; CELL SEPARATION; EXTRACELLULAR MATRIX; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE, CHRONIC; MACROPHAGE ACTIVATION; MALE; MATRIX METALLOPROTEINASES; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEUTROPHILS; RENAL DIALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SUBCELLULAR FRACTIONS;

EID: 39149133657     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00952.2007     Document Type: Article

References (50)

1. Bartlett MR, Underwood PA, Parish CR. Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: evidence for cytokine dependence and detection of a novel sulfatase. Immunol Cell Biol 73: 113-124, 1995.
2. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-777, 1999.
3. Chen G, Wang D, Vikramadithyan R, Yagyu H, Saxena U, Pillarisetti S, Goldberg IJ. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 43: 4971-4977, 2004.
4. Chen MF, Chang CL, Liou SY. Increase in resting levels of superoxide anion in the whole blood of uremic patients on chronic hemodialysis. Blood Purif 16: 290-300, 1998.
5. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 20: 1898-1900, 2006.
6. Dewald B, Bretz U, Baggiolini M. Release of gelatinase from a novel secretory compartment of human neutrophils. J Clin Invest 70: 518-525, 1982.
7. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96: 1219-1230, 2004.
8. Ethuin F, Chollet-Martin Sylvie. Cytokine production by neutrophils. In: The neutrophils - new outlook for old cells, edited by Gabrilovich DI. London: Covent Garden, 2005, p. 229-251.
9. Gingis-Velitski S, Zetser A, Kaplan V, Ben-Zaken O, Cohen E, Levy-Adam F, Bashenko Y, Flugelman MY, Vlodavsky I, Ilan N. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 279: 44084-44092, 2004.
10. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38: 2018-2039, 2006.
11. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67: 609-652, 1998.
12. Jacobi J, Sela S, Cohen HI, Chezar J, Kristal B. Priming of polymorphonuclear leukocytes: a culprit in the initiation of endothelial cell injury. Am J Physiol Heart Circ Physiol 290: H2051-H2058, 2006.
13. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 10: 267-274, 2003.
14. Kawagishi T, Nishizawa Y, Konoshi T, Kawasaki K, Emoto M, Shoji T, Tabata T, Inoue T, Morii H. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 48: 820-826, 1995.
15. Kim C, Vaziri ND. Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 67: 1028-1032, 2005.
16. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 60: 443-475, 1991.
17. Kramer A, van den Hoven M, Rops A, Wijnhoven T, van den Heuvel L, Lensen J, van Kuppevelt T, van Goor H, van der Vlag J, Navis G, Berden JH. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 17: 2513-2520, 2006.
18. Kristal B, Shurtz-Swirski R, Shapiro G, Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens 11: 921-928, 1998.
19. Krug MS, Berger SL. First-strand cDNA synthesis primed with oligo(dT). Methods Enzymol 152: 316-325, 1987.
20. + T cell apoptosis in patients with end-stage renal disease through Fas engagement. J Am Soc Nephrol 18: 331-342, 2007.
21. Michelis R, Sela S, Kristal B. Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels. Nephrol Dial Transplant 20: 1963-1969, 2005.
22. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999.
23. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochem Biophys Acta 1471: 99-108, 2001.
24. Pawlak K, Pawlak D, Mysliwiec M. Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 190: 199-204, 2007.
25. Pikas DS, Li JP, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 273: 18770-18777, 1998.
26. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 100: 867-874, 1997.
27. Rops AL, van der Vlag J, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH, Berden JH. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 65: 768-785, 2004.
28. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126, 1999.
29. Rysz J, Banach M, Cialkowska-Rysz A, Stolarek R, Barylski M, Drozdz J, Okonski P. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol 3: 151-154, 2006.
30. Schaefer RM, Herfs N, Ormanns W, Horl WH, Heidland A. Change of elastase and cathepsin G content in polymorphonuclear leukocytes during hemodialysis. Clin Nephrol 29: 307-311, 1988.
31. Schettler A, Thorn H, Jockusch BM, Tschesche H. Release of proteinases from stimulated polymorphonuclear leukocytes. Evidence for subclasses of the main granule types and their association with cytoskeletal components. Eur J Biochem 197: 197-202, 1991.
32. Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 16: 2431-2438, 2005.
33. Shurtz-Swirski R, Sela S, Herskovits AT, Shasha SM, Shapiro G, Nasser L, Kristal B. Involvement of polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetes. Diabetes Care 24: 104-110, 2001.
34. Sivaram P, Obunike JC, Goldberg IJ. Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. J Biol Chem 270: 29760-29765, 1995.
35. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999.
36. Swain SD, Rohn TT, Quinn MT. Neutrophil priming in host defense: role of oxidants as priming agents. Antioxid Redox Signal 4: 69-83, 2002.
37. Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol 67: 149-159, 2000.
38. van den Born J, Gunnarsson K, Bakker MA, Kjellen L, Kusche-Gullberg M, Maccarana M, Berden JH, Lindahl U. Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody. J Biol Chem 270: 31303-31309, 1995.
39. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, Goldschmeding R, Zcharia E, Vlodavsky I, van der Vlag J, Berden JH. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70: 2100-2108, 2006.
40. Villanueva ME, Zaher FM, Svinarich DM, Konduri GG. Decreased gene expression of endothelial nitric oxide synthase in newborns with persistent pulmonary hypertension. Pediatr Res 44: 338-343, 1998.
41. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108: 341-347, 2001.
42. Vlodavsky I, Abboud-Jarrous G, Elkin M, Naggi A, Casu B, Sasisekharan R, Ilan N. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 35: 116-127, 2006.
43. Vlodavsky I, Bar-Shavit R, Korner G, Fuks Z. Extracellular matrix-bound growth factors, enzymes and plasma proteins. In: Basement membranes: cellular and molecular aspects, edited by Rohrbach DH and Timple R. Orlando, Florida: Academic Press, 1993, p. 327-343.
44. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR, Fuks Z. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12: 112-127, 1992.
45. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5: 793-802, 1999.
46. Vreys V, Delande N, Zhang Z, Coomans C, Roebroek A, Durr J, David G. Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem 280: 33141-33148, 2005.
47. Ward RA, Ouseph R, McLeish KR. Effects of high-flux hemodialysis on oxidant stress. Kidney Int 63: 353-359, 2003.
48. Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 71: 167-172, 2007.
49. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117: 2249-2258, 2004.
50. Zoungas S, Ristevski S, Lightfoot P, Liang YL, Branley P, Shiel LM, Kerr P, Atkins R, McNeil JJ, McGrath BP. Carotid artery intimamedial thickness is increased in chronic renal failure. Clin Exp Pharmacol Physiol 27: 639-641, 2000.